Maintenance Therapy With Ponatinib After Allogeneic HSCT in Philadelphia Chromosome–Positive ALL With T315I Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation
Leuk. Res 2022 Oct 01;121(xx)106930, H Chen, LP Xu, XH Zhang, Y Wang, YH Chen, CH Yan, YF Cheng, W Han, Y Chen, YZ Qin, Y Liu, YJ Chang, KY Liu, XJ HuangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.